LLY

745.65

-0.79%↓

JNJ

148.78

-3.72%↓

UNH

319.44

-15.48%↓

ABBV

188.31

-1.36%↓

ABT

129.75

-2.06%↓

LLY

745.65

-0.79%↓

JNJ

148.78

-3.72%↓

UNH

319.44

-15.48%↓

ABBV

188.31

-1.36%↓

ABT

129.75

-2.06%↓

LLY

745.65

-0.79%↓

JNJ

148.78

-3.72%↓

UNH

319.44

-15.48%↓

ABBV

188.31

-1.36%↓

ABT

129.75

-2.06%↓

LLY

745.65

-0.79%↓

JNJ

148.78

-3.72%↓

UNH

319.44

-15.48%↓

ABBV

188.31

-1.36%↓

ABT

129.75

-2.06%↓

LLY

745.65

-0.79%↓

JNJ

148.78

-3.72%↓

UNH

319.44

-15.48%↓

ABBV

188.31

-1.36%↓

ABT

129.75

-2.06%↓

Search

Xenon Pharmaceuticals Inc

Open

SectorGezondheidszorg

29.95 -16.62

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.21

Max

36.27

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.9M

-66M

EPS

-0.84

Werknemers

316

EBITDA

-3.8M

-77M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+57.05% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

6.7M

2.9B

Vorige openingsprijs

46.57

Vorige sluitingsprijs

29.95

Nieuwssentiment

By Acuity

22%

78%

49 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2025, 22:34 UTC

Acquisities, Fusies, Overnames

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mei 2025, 23:48 UTC

Marktinformatie

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12 mei 2025, 23:46 UTC

Marktinformatie

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12 mei 2025, 23:34 UTC

Marktinformatie

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12 mei 2025, 23:21 UTC

Marktinformatie

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12 mei 2025, 22:54 UTC

Marktinformatie

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12 mei 2025, 22:43 UTC

Winsten

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12 mei 2025, 22:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mei 2025, 22:08 UTC

Acquisities, Fusies, Overnames

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12 mei 2025, 22:08 UTC

Acquisities, Fusies, Overnames

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12 mei 2025, 22:07 UTC

Acquisities, Fusies, Overnames

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12 mei 2025, 22:07 UTC

Acquisities, Fusies, Overnames

Ampol to Sell Australia Retail Electricity Business to AGL

12 mei 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12 mei 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12 mei 2025, 22:05 UTC

Acquisities, Fusies, Overnames

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12 mei 2025, 22:04 UTC

Acquisities, Fusies, Overnames

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mei 2025, 21:15 UTC

Top Nieuws

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12 mei 2025, 21:01 UTC

Winsten

Constellation Software 1Q Rev $2.65B >CSU.T

12 mei 2025, 21:01 UTC

Winsten

Constellation Software 1Q Net $115M >CSU.T

12 mei 2025, 21:01 UTC

Winsten

Constellation Software 1Q EPS $5.44 >CSU.T

12 mei 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

12 mei 2025, 20:50 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

12 mei 2025, 20:44 UTC

Top Nieuws

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12 mei 2025, 20:31 UTC

Top Nieuws

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12 mei 2025, 20:24 UTC

Winsten

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12 mei 2025, 20:24 UTC

Winsten

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12 mei 2025, 20:24 UTC

Top Nieuws

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12 mei 2025, 20:22 UTC

Acquisities, Fusies, Overnames

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12 mei 2025, 20:15 UTC

Winsten

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12 mei 2025, 20:10 UTC

Winsten

Blink Charging 1Q Rev $20.8M >BLNK

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

57.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55 USD  57.05%

Hoogste 65 USD

Laagste 42 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

14

Buy

0

Hold

0

Sell

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

49 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.